Navigation Links
DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
Date:9/6/2011

CUPERTINO, Calif., Sept. 6, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the dosing of the last patient in the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST (Bupivacaine Effectiveness and Safety in SABER trial).  POSIDUR is a post-operative pain relief depot that utilizes DURECT's patented SABER™ technology to deliver bupivacaine to provide up to three days of pain relief after surgery.  DURECT expects to report top-line data from the BESST trial in the fourth quarter of 2011 and, if the data are positive, to submit the New Drug Application in the first half of 2012.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

"We believe that POSIDUR has the potential to play a major role in treating post-surgical pain, reducing the need for systemic narcotics and associated side effects, as well as costs associated with extended hospital stays," stated James E. Brown, President and CEO.

"We are encouraged by this important development milestone for POSIDUR, an innovative product candidate which may represent a significant step-forward in the management of acute pain for patients following surgical procedures. Hospira is committed to bringing POSIDUR to market rapidly following FDA review and approval," added Andrew Robbins, Vice President, corporate development at Hospira, Inc. POSIDUR is licensed to Hospira (NYSE: HSP) for commercialization in the U.S. and Canada.

About the Design of BESST

BESST is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety, efficacy, effectiveness, and pharmacokinetics of POSIDUR in 305 patients undergoing a variety of general abdominal surgical proce
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DURECT Corporation to Participate in Upcoming Healthcare Conferences
2. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
3. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
4. DURECT to Present at the Jefferies Healthcare Conference
5. DURECT Announces Resignation of Chief Medical Officer
6. DURECT to Present at the UBS Global Specialty Pharmaceuticals Conference
7. DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
8. DURECT to Present at Cowen and Company Health Care Conference
9. DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call
10. DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
11. DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... N.C. , April 28, 2015 Chiltern, a ... Year (CRoY) winners in the UK, joining the five finalists ... the Gold Pharma in the CTA category and Helen ... Source professionals are working with Novartis. "We are ... as top performers in the industry," commented Nannette Penny ...
(Date:4/28/2015)... Minn. , April 28, 2015 ANI ... the Company plans to release its first quarter 2015 ... opening of the U.S. financial markets. The earnings press ... of the Company,s website, www.anipharmaceuticals.com . ... Executive Officer, and Charlotte C. Arnold , Vice ...
(Date:4/28/2015)... , April 28, 2015  Rosa & Co. ... drug-disease modeling and simulation, today announced its pleasure to ... exciting field of Quantitative Systems Pharmacology (QSP). The conference ... drug development.  ... Rosa,s lead sponsorship ...
Breaking Medicine Technology:Chiltern expands PharmaTimes Clinical Researcher of the Year involvement as sponsor, host and winner 2Chiltern expands PharmaTimes Clinical Researcher of the Year involvement as sponsor, host and winner 3ANI Pharmaceuticals Schedules Conference Call for First Quarter 2015 Financial Results 2Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 2Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 3
... a,licensee of Vical Incorporated (Nasdaq: VICL ), ... 3 clinical trial of its NV1FGF,angiogenesis therapy, which ... successful completion of the trial, called TAMARIS,sanofi-aventis expects ... The plasmid DNA (pDNA) therapy encodes Fibroblast Growth ...
... division of Wyeth (NYSE: WYE ), presented ... a selective estrogen receptor,modulator, at the American Society ... three-year study, data showed that bazedoxifene 20 mg ... new vertebral fractures by 42,percent and 37 percent, ...
Cached Medicine Technology:Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations 2Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations 3Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 2Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 3Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 4
(Date:4/28/2015)... FL (PRWEB) April 28, 2015 Two ... System were named to Becker's Hospital Review’s list ... . Peter Pronovost, M.D., Ph.D. , director of ... and senior vice president for patient safety and ... M.D., M.H.C.M. , vice president of medical affairs and ...
(Date:4/28/2015)... BC (PRWEB) April 28, 2015 Vancouver ... a blog stating that it is smarter to call ... a personal injury claim. The blog reasons that there ... since these professional are well-versed with the law and ... client would be able to on their own. Competent ...
(Date:4/28/2015)... 28, 2015 The popular all-natural supplement ... for their newly launched L-Style Revolution Program™, and collectively ... counting in just two short months. The customized ... exercise plan for men and women of all health ... loss and weight maintenance goals faster than traditional methods. ...
(Date:4/28/2015)... April 28, 2015 MSA Executive ... executive search, announced today that it has been retained ... Operating Officer search for The Queen's Health ... Reporting to QHS President & CEO Arthur A. Ushijima, ... have operating responsibility for the Queen’s Medical Center Punchbowl ...
(Date:4/28/2015)... Pittsburgh, PA (PRWEB) April 28, 2015 ... by Blair A. Jobe, MD, FACS , has ... replacing esophageal tissue with extracellular matrix (ECM) can help ... lethal form of esophageal cancer. , ECM is a ... for cell attachment and migration and signals that guide ...
Breaking Medicine News(10 mins):Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 4Health News:Vancouver Personal Injury Lawyers Recently Stated in Latest Blog That It Is Smarter To Call A Lawyer Before ICBC 2Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 2Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 3Health News:The Queen’s Health Systems Retains MSA Executive Search to Recruit Executive Vice President & Chief Operating Officer 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3
... health, , THURSDAY, Feb. 18 (HealthDay News) -- New research ... a lot and those who have them less often: The ... more depressed. , The finding comes from a study ... episodic, if they occurred no more than 14 days a ...
... ... than later, says substance abuse expert Glenn Williams in his new Authentic/Biblica book, Talking Smack ... (PRWEB) February 18, 2010 ... COO Glenn Williams, a psychologist and substance abuse expert who has worked with parents and ...
... ... Carnie Wilson, will host a blog on The Fresh Diet, chronicling her quest to whittle ... Corner at blog.thefreshdiet.com where the daughter of the legendary Beach Boy, Brian Wilson, will discuss ... , ...
... ... related Q&A and social networking site, grows and adds new offerings, including answer customization ... ... SciAnswers.com , launched just over three months ago in November 2009 as a science ...
... ... freight import records from the public. Meanwhile, Microsoft, Google and Sony continue to import ... ... 17, 2010 -- Trade Privacy LLC , a trade data protection company, just ...
... , , , ... Ensign Group, Inc. (Nasdaq: ENSG ), the parent company of ... and assisted living companies, today reported record results for the fourth ... , Financial Highlights Include: , Total ...
Cached Medicine News:Health News:Talking Smack to Keep Kids Drug-Free 2Health News:Talking Smack to Keep Kids Drug-Free 3Health News:Carnie Wilson Blogs On The Fresh Diet 2Health News:SciAnswers.com Grows and Adds a Technical and Healthcare Professionals Job Board. 2Health News:SciAnswers.com Grows and Adds a Technical and Healthcare Professionals Job Board. 3Health News:Trade Privacy LLC: Research Concludes Apple Inc. Has Blocked Their Import Records from Public Access 2Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 2Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 3Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 4Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 5Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 6Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 7Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 8Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 9Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 10Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 11Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 12Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 13Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 14Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 15Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 16
... Introducing the new large ... new handpieces function as both ... the ultimate in flexibility. Its ... always wanted with the security ...
... 7600 Oscillating Saw offers unparalleled ... thanks to its 14.4V NiMH ... head may be rotated into ... any plane and will accept ...
... Breakthrough in Battery Powered Orthopedic Systems., ... new addition to the Hall® Surgical line ... System is the first and only software ... market. It is a full-function orthopedic power ...
... Introducing the new large ... Our new handpieces function ... electric instruments, offering the ... the versatility the industry ...
Medicine Products: